

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/635,696  
Applicant: Rapin, *et al.*  
Filed: August 5, 2003  
Title: Tripeptide Derivatives for the Treatment of  
Neurodegenerative Diseases  
TC/A.AU.: 1632  
Examiner: To be assigned  
  
Docket No.: 10945.105001 (Neuro 100)  
Customer No.: 20786

Confirmation No.: 8343

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


**Supplemental Information Disclosure Statement**

Sir:

The citation of information on the attached Form PTO-1449 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. Copies of all references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

This Supplemental Information Disclosure Statement is being submitted before the mailing of a first Office action on the merits, thus under the provisions of 37 CFR §1.97(b)(3) we do not believe that the fee set forth under §1.17(p) applies or is due. If however a fee is due, the Examiner is authorized to charge any fees or credit any overpayment to Deposit Account No. 11-0980.


Respectfully submitted,

  
Madeline I. Johnston  
Reg. No. 36,174


April 1, 2004  
King & Spalding, LLP  
191 Peachtree Street, N.E., Atlanta, GA 30303  
Office: (404)572-4600/ Fax: 404-572-5145

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on April 1, 2004.

  
Tisha Hardrick

3444630\_1.DOC



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)  Sheet <b>1</b> of <b>1</b>				<b>Complete if Known</b>	
				Application Number	<b>10/635,696</b>
				Filing Date	<b>August 5, 2003</b>
				First Named Inventor	<b>Rapin, et al.</b>
				Group Art Unit	<b>1632</b>
				Examiner Name	<b>Unassigned</b>
				Attorney Docket Number	<b>10945.105001 Neuro 100</b>

3383682\_2

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
		<i>None</i>				

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
			<i>None</i>					

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	AA	FADEN, A.I., et al., "Effect of TRH analogs on neurologic recovery after experimental spinal trauma," <i>Neurology</i> , 35:1331-1334 (1985).	
	AB	GESCHWIND, M., et al., "Detection of apoptotic or necrotic death in neuronal cells by morphological, biochemical, and molecular analysis," in <i>Apoptosis Techniques and Protocols</i> , J. Poirier, ed., 1997, pp. 13-31.	
	AC	GUILOFF, R.J., "Thyrotropin releasing hormone and motoneurone disease", <i>Reviews in the Neurosciences</i> , 1:201-219 (1987).	
	AD	KURTZ, A.F., "Praktische Diagnostik," in <i>Aktuelles Wissen Hoechst, Alzheimer-Patienten erkennen und behandeln</i> , Hoechst AG, publisher (Munich, Germany, 1995), 68-69. <i>With partial translation.</i>	partial
	AE	RAPIN, J.R., "Les nootropes: propriétés pharmacologiques du piracétam et indications thérapeutiques," <i>La Lettre du Pharmacologue</i> , 6(5):108-111 (1992). <i>With partial translation.</i>	partial
	AF	SARTI, G., et al., "TRH-analogues: A possible treatment for symptoms of dementia in elderly patients?", <i>Archives of Gerontology and Geriatrics</i> , 12:173-177 (1991).	
	AG	SZIRTES, T., et al., "Synthesis of thyrotropin-releasing hormone analogues. 1. Complete dissociation of central nervous system effects from thyrotropin-releasing activity," <i>J. Med. Chem.</i> 27:741-745 (1984).	

3383682\_2

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.